- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00693173
Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients
Genital Drop Technique With Intensity-Modulated Radiation Therapy (IMRT) in Male Anal and Distal Rectal Cancer Patients: A Dosimetric Comparison
Study Overview
Status
Conditions
Detailed Description
This is a study of two different setups when treating a patient with standard of care radiation doses. The study compares two patient setups (Standard Prone vs. Genital Drop Technique) with identical radiation treatment technique and parameters. After the two setups have been planned, the treating faculty reviews the setups and will choose the setup he feels that will give the patient improved dosimetry to the local regions and hopefully reduce toxicity and improve treatment tolerability.
Patients will not be randomized or stratified by demographic or disease risk assessment, but treatment will be tailored to stage specific current standards of care.
An extra (non standard of care) CT is required to analyze the data.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77550
- The University of Texas Medical Branch at Galveston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically proven anal cancer (squamous, basaloid, or cloacogenic carcinoma) or distal rectal cancer (adenocarcinoma variants) that traverse the dentate line and are eligible for definitive chemoradiation or preoperative radiation therapy, respectively.
- Any histological grade.
- Age: >18 years.
- Gender: Male patients with average external genitalia.
- Race: Any.
- Language: English speaking only.
- Performance status: Good (Karnofsky Performance Status of >60%). (ECOG 0-2).
- UTMB patients
- Stages: Early local disease to locoregionally advanced disease per the 2002 American Joint Committee on Cancer (AJCC) Staging System.
- Anal Cancer: Stages I-IIIB (see Section 11).
- Distal Rectal Cancers that pass the dentate line and into the anal canal only: Stages IIA-IIIC (see Section 11).
Exclusion Criteria
- Histological variants other than those listed above in 4.a.
- Patients with cystocele or abnormal scrotal edema will be excluded. (Although the Genital Drop Technique may specifically benefit this group of patients, however this study is to be performed with average patient anatomy).
- 2002 American Joint Committee on Cancer (AJCC) Staging System. (Anal Cancer: Stage IV.; Distal Rectal Cancer: Stage IV, and tumor 2-node 0-metastasis 0 (T1-T2N0M0) patients).
- Performance status: Poor (Karnofsky Performance Status of <60%). (ECOG 3-4).
- Non-English speaking patients.
- Prior pelvic radiation.
- Prior pelvic malignancy.
- Anal cancer/rectal cancer surgery, except for biopsy at study site.
- Patient's mental condition and social support is such that he can neither understand the nature of the protocol nor comply with its requirements.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.
Time Frame: Day 1. Pretreatment analysis.
|
The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles, scrotal skin and penile shaft compared to the standard conformal radiation therapy (CRT) and IMRT plans while preserving adequate planned target volume (PTV) dose coverage and homogeneity to the target organs in male anal cancer patients.
|
Day 1. Pretreatment analysis.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dosimetry comparison details.
Time Frame: Day 1. Pretreatment parameters.
|
Testicular dose: Volume receiving 14 Gy was 90% with CRT, 64% with IMRT, and 3% with IMRT-GD. Testicular dose: Volume receiving 30 Gy was 54% with CRT, 26% with IMRT, and 0% with IMRT-GD. External genitalia dose: Volume receiving 14 Gy was 93% with CRT, 79% with IMRT, and 35% with IMRT-GD. External genitalia dose: Volume receiving 30 Gy was 75% with CRT, 31% with IMRT, and 12% with IMRT-GD. Planning Target Volume receiving full 54 Gy dose was 93% with CRT, 93% with IMRT, and 94% with IMRT-GD. |
Day 1. Pretreatment parameters.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Grant R. Seeger, MD, The University of Texas Medical Branch at Galveston
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8 | Stage 0 Anal Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
Sun Yat-sen UniversityCompletedAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage IIIChina
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8United States, Canada
-
Emory UniversityNational Cancer Institute (NCI)RecruitingStage IIIB Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage 0 Anal Cancer AJCC v8 | Localized Anal Carcinoma | Localized Anal Margin CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Squamous Cell Carcinoma | Recurrent Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IV Anal Cancer AJCC v8 | Unresectable Anal Squamous Cell CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal CancerUnited States
-
Cardiff UniversityActive, not recruitingAnal Cancer Stage III A | Anal Cancer Stage III BUnited Kingdom, Norway
-
National Cancer Institute (NCI)Active, not recruitingStage IV Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Metastatic Anal Canal CarcinomaUnited States, Canada